In accordance with our cell-based cPLS data (Figure 1), Prdx2 KO reversed the PLS poor-prognosis status to a good-prognosis status, supporting the hypothesis that targeting Prdx2 in hepatocytes reduces the HCC risk (Figure 3B). Here, PRDX2 is linked to hepatocellular carcinoma.